Sulfatide inhibits fibroblast growth, activation and oxidative stress induced by ectopic insulin

Diabetes Obes Metab. 2023 Sep;25(9):2514-2525. doi: 10.1111/dom.15123. Epub 2023 May 29.

Abstract

Aim: To study the effect of sulfatide on gene expression and proliferation of human primary fibroblasts induced by insulin, insulin-like growth factor-1 and human growth hormone.

Materials and methods: Human primary fibroblasts were exposed to 1, 3 and 30 μM of sulfatide or its precursor galactosylceramide (GalCer). Proliferation was determined by 3 H-thymidine incorporation and gene expression via microarray analysis.

Results: Sulfatide and GalCer reduced the growth rate of fibroblasts by 32%-82% when exposed to 0.5 nM insulin. After challenge with 120 μM of H2 O2 , sulfatide reduced membrane leakage. Fibroblast gene expression was altered by sulfatide in gene pathways associated with cell cycle/growth, transforming growth factor-β function, and encoding of proteins involved in intracellular signalling. NFKBIA, a key control element in NF-кB regulation, was decreased 2-fold by sulfatide.

Conclusions: Sulfatide strongly inhibits fibroblast growth. We therefore suggest the addition of sulfatide to injectable commercial insulin formulations, which would reduce adverse fibroblast growth and improve well-being in patients with diabetes.

Keywords: beta cell devices; fibroblasts; sphingolipids; sulfatide; type 1 diabetes.

MeSH terms

  • Fibroblasts / metabolism
  • Humans
  • Insulin* / metabolism
  • Insulin* / pharmacology
  • Insulin, Regular, Human
  • Oxidative Stress
  • Sulfoglycosphingolipids* / metabolism
  • Sulfoglycosphingolipids* / pharmacology

Substances

  • Insulin
  • Sulfoglycosphingolipids
  • Insulin, Regular, Human